ATXN2 trinucleotide repeat length correlates with risk of ALS by Sproviero, William et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.neurobiolaging.2016.11.010
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Sproviero, W., Shatunov, A., Stahl, D., Shoai, M., van Rheenen, W., Jones, A. R., ... Al-Chalabi, A. (2016).
ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiology of Aging.
10.1016/j.neurobiolaging.2016.11.010
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
ATXN2 trinucleotide repeat length correlates with risk of ALS
William Sproviero a, Aleksey Shatunov a, Daniel Stahl b, Maryam Shoai c,
Wouter van Rheenen d, Ashley R. Jones a, Safa Al-Sarraj e, Peter M. Andersen f,
Nancy M. Bonini g, Francesca L. Conforti h, Philip Van Damme i,j,k, Hussein Daoud l,
Maria Del Mar Amadorm, Isabella Fogh a, Monica Forzan n, Ben Gaastra a, Cinzia Gellera o,
Aaron D. Gitler p, John Hardy c, Pietro Fratta q, Vincenzo La Bella r, Isabelle Le Ber s,t,
Tim Van Langenhove u,v,w, Serena Lattante s, Yi-Chung Lee x,y,z, Andrea Malaspina aa,
Vincent Meininger bb,cc, Stéphanie Millecamps s, Richard Orrell dd, Rosa Rademakers ee,
Wim Robberecht j,k, Guy Rouleau l, Owen A. Ross ee, Francois Salachasm,s, Katie Sidle c,
Bradley N. Smith a, Bing-Wen Soong x,y,z, Gianni Sorarù ff, Giovanni Stevanin s,gg,
Edor Kabashi s, Claire Troakes a, Christine van Broeckhoven u,v, Jan H. Veldink d,
Leonard H. van den Berg d, Christopher E. Shawa, John F. Powell a, Ammar Al-Chalabi a,*
aDepartment of Basic and Clinical Neuroscience, King’s College London, Maurice Wohl Clinical Neuroscience Institute, London, UK
bDepartment of Biostatistics, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK
cDepartment of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK
dDepartment of Neurology, Brain Center Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, the Netherlands
eDepartment of Clinical Neuropathology, King’s College Hospital NHS Foundation Trust, London, UK
fDepartment of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden
gDepartment of Biology, University of Pennsylvania, Philadelphia, PA, USA
h Institute of Neurological Sciences, National Research Council, Cosenza, Italy
iNeurology Department, University Hospitals Leuven, Leuven, Belgium
jVesalius Research Center, VIB, Leuven, Belgium
kDisease (LIND), KU Leuven - University of Leuven, Leuven, Belgium
lMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada
mDepartment of Nervous System Diseases, ALS Paris ALS Center for Rare Diseases, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France
nClinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy
o Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
pDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA
q Sobell Department of Motor Neuroscience and Movement Disorders, University College London (UCL) Institute of Neurology, London, UK
rALS Clinical Research Center, Bio. Ne. C., University of Palermo, Palermo, Italy
s Institut du Cerveau et de la Moelle épinière (ICM), Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMRS1127, Paris, France
tAP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Centre de Référence des Démences Rares, Departement de Neurologie, Paris, France
uNeurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium
v Laboratory of Neurogenetics, Insititute Born-Bunge, University of Antwerp, Antwerp, Belgium
wDepartment of Neurology, Antwerp University Hospital, Edegem, Belgium
xDepartment of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan
yDepartment of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan
zBrain Research Center, National Yang-Ming University, Taipei, Taiwan
aaNorth-East London and Essex MND Care Centre - Neuroscience and Trauma Centre, Blizard, Institute of Cell and Molecular Medicine, Barts & the
London School of Medicine & Dentistry, Barts Health NHS Trust, London, UK
bbHôpital de la Pitié-Salpêtrière, institut de recherche translationnelle en neurosciences (A-ICM), Paris, France
ccHôpital de la Pitié-Salpêtrière, réseau SLA IdF, Paris, France
ddDepartment of Clinical Neuroscience, University College London (UCL) Institute of Neurology, London, UK
eeDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
ffDepartment of Neurosciences, University of Padova, Padova, Italy
ggNeurogenetics team, Ecole Pratique des Hautes Etudes, Paris, France
* Corresponding author at: Department of Basic and Clinical Neuroscience, King’s
College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road,
Camberwell, London SE5 9RX, UK. Tel.: 020 7848 5192; fax: 020 7848 5190.
E-mail address: ammar.al-chalabi@kcl.ac.uk (A. Al-Chalabi).
Contents lists available at ScienceDirect
Neurobiology of Aging
journal homepage: www.elsevier .com/locate/neuaging
0197-4580/ 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.neurobiolaging.2016.11.010
Neurobiology of Aging 51 (2017) 178.e1e178.e9
a r t i c l e i n f o
Article history:
Received 1 September 2016
Received in revised form 14 November 2016
Accepted 16 November 2016
Available online 24 November 2016
Keywords:
ATXN2
SCA2
ALS
CAG
Expansion
Intermediate expansion
Trinucleotide repeat
Amyotrophic lateral sclerosis
Age of onset
Risk
Exponential risk
Triplet
a b s t r a c t
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis
(ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch
dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we system-
atically searched PubMed for case-control studies published after 1 August 2010 that investigated the
association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and
existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG
trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate
sized trinucleotide repeat alleles (odds ratio 3.06 [95% conﬁdence interval 2.37e3.94]; p ¼ 6  1018),
with an exponential relationship between repeat length and ALS risk for alleles of 29e32 repeats (R2 ¼
0.91, p ¼ 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to
trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict
age of onset but does predict disease risk.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Spinocerebellar ataxia type 2 is a trinucleotide repeat disease
in which neurodegeneration is a consequence of expansion of a
repeated CAG sequence in the ATXN2 gene. All trinucleotide
repeat diseases show neurological features and include Hunting-
ton’s disease (Paulsen et al., 2014), the spinocerebellar ataxias
(Tezenas du Montcel et al., 2014), Friedreich’s ataxia (Koeppen,
2011), fragile X syndrome (Jin and Warren, 2000), myotonic dys-
trophy (Khoshbakht et al., 2014), and Kennedy’s disease (Yang and
Yamamoto, 2014) among others. The mechanism by which the
repeated sequence causes disease remains unknown, but a
frequently observed feature is a relationship between age of
symptom onset, severity of phenotype, and repeat size, with larger
repeats associated with younger onset and more severe disease
(Nestor and Monckton, 2011).
Intriguingly, trinucleotide repeat expansion in the ATXN2 gene is
also a risk factor for amyotrophic lateral sclerosis (ALS), a neuro-
degenerative disease of upper and lower motor neurons, but this
association is only seen for repeats of intermediate size, below the
range usually associated with spinocerebellar ataxia (34 repeats or
more) but above the normal range (Elden et al., 2010). Such
pleiotropy is not seen in other trinucleotide repeat diseases and
means that the usually observed relationship between repeat size,
age of onset, and severity, might not be straightforward. Here, we
investigate the size range deﬁning ALS risk and test the relationship
of phenotype with repeat size.
2. Methods
2.1. Unpublished case-control studies
A total of 1474 UK DNA samples of unrelated ALS patients
(29 with an affected ﬁrst degree relative) were collected from a
consecutive clinical case series obtained from King’s College Hos-
pital (n ¼ 116), from the Motor Neurone Disease Association DNA
Biobank (n¼ 1051), and fromQueenMary University of London and
UCL Institute of Neurology (n¼ 307). All patients were diagnosed as
having deﬁnite or probable ALS according to the El Escorial criteria.
The DNA samples of 567 neurologically normal controls, matched to
patients for gender, age, and geographical region, were obtained
from the MRC London Neurodegenerative Diseases Brain Bank, the
Institute of Psychiatry, Psychology and Neuroscience (n ¼ 68), from
the National Institute for Health Research Mental Health Biomed-
ical Research Centre and the Dementia Unit at South London and
Maudsley NHS Foundation Trust and the Institute of Psychiatry,
King’s College London (n ¼ 306), and from the Motor Neurone
Disease Association (n ¼ 193).
A second case-control population-based set was obtained in
collaboration with the University Medical Center Utrecht, the
Netherlands, with a total of 1328 unrelated ALS cases (23 with a
family history in a ﬁrst degree relative) and 691 neurologically
normal controls, matched to patients for gender, age, and
geographical region (Liberati et al., 2009). Samples used did not
overlap with previous studies of ATXN2 repeat size.
2.2. Standard protocol approvals, registrations, and patient
consents
Informed consent was obtained from all included in the study.
The study was approved by the Trent Research Ethics Committee
08/HO405/60 and by the Medical Ethics Review Board at the Uni-
versity Medical Center Utrecht 05_067/E.
2.3. Genetic analysis
The DNA samples of 1167 ALS cases and 567 controls were
analyzed at the Institute of Psychiatry, Psychology and Neurosci-
ence, King’s College London, and DNA samples of 307 ALS cases
underwent analysis at the Institute of Neurology, UCL. The ATXN2
CAG trinucleotide repeat region was ampliﬁed according to a pre-
viously published PCR protocol (Pulst et al., 1996). PCR products at
King’s College London were run on an Applied Biosystems 3130xl
Genetic Analyzer, and those at UCL on an Applied Biosystems
3730xl Genetic Analyzer. PCR fragments were analyzed using
GeneMapper V 4.0 software (Applied Biosystems) to determine
CAG trinucleotide repeat size. Electropherogram peaks were sized
using GeneScanTM 500 LIZ as reference dye labeled standard.
Sequenced samples of known CAG trinucleotide repeat size were
used as internal controls for both PCR and GeneScan analysis. PCR
products of cases and controls with more than 26 repeats were
regenotyped to validate the obtained results.
The DNA samples of 1328 Dutch ALS cases and 691 controls
underwent ATXN2 CAG trinucleotide repeat ampliﬁcation according
to a previously reported PCR protocol (Van Damme et al., 2011). PCR
products were analyzed using an Applied Biosystems 3130xl
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Genetic Analyzer. PCR fragments were analyzed using GeneMapper
V 4.0 software (Applied Biosystems) to determine CAG trinucleotide
repeat size. Electropherogram peaks were sized using GeneScanTM
500 LIZ as reference dye labeled standard. Sequenced samples of
known CAG trinucleotide repeat size were used as internal controls
for both PCR and GeneScan analysis. PCR products of cases and
controls with more than 26 repeats were regenotyped to validate
the obtained results.
Samples were also genotyped for C9orf72 expansion as described
previously (See Supplementary Material).
2.4. Inclusion criteria for published studies
Systematic review and meta-analysis were conducted in accor-
dance with the PRISMA (Huisman et al., 2011; Preferred Reporting
Items for Systematic reviews and Meta-Analyses) group guidelines
and Cochrane Collaboration. The types of studies included were
case-control studies designed to evaluate the minimum number of
CAG repeats in the ATXN2 gene conferring risk for ALS. Series of
cases and descriptive reports were excluded from study selection.
Repeats of size 23 or less were regarded as normal given their high
control frequency in several populations (Lafﬁta-Mesa et al., 2012).
2.5. Study design, data extraction, and control of bias
This was not an interventional study and therefore was not
randomized or blinded. Study selection was restricted to case-
control studies published after 1 August 2010, the date of the ﬁrst
reported association between ATXN2 variation and ALS. The exact
frequencies of each allele with 24 repeats or greater, and the pooled
counts of alleles frequencies with less than 24 repeats were
extracted for both cases and controls from published papers. ALS
diagnostic criteria, control recruitment information, and case-
control matching for age and geographical region were extracted
to ensure comparability between studies. Where ATXN2 allele fre-
quencies or information about control selection and case-control
age matching were incomplete, study authors were contacted.
Data extraction was performed in duplicate by 2 independent in-
vestigators (William Sproviero, Aleksey Shatunov). The new case-
control studies from UK and Dutch populations were included in
the analysis. Bias in individual studies was evaluated using the
Newcastle-Ottawa Scale questionnaire for Quality Assessment of
Nonrandomized Studies (Stang, 2010). The questionnaire contains
8 items subdivided into 3 categories (selection, comparability, and
exposure), with a maximum overall score of 8. Studies with total
score equal or greater than 6 were considered at low risk of bias.
2.6. Statistical methods
Relative risks (RRs) were approximated by the odds ratio,
generated with corresponding 95% conﬁdence intervals (CIs), by
meta-analysis using a Cochran-Mantel-Haenszel chi-square test
comparing the case-control counts for a speciﬁc allele with the
pooled counts for alleles of 23 repeats or fewer across the different
published and unpublished studies. RR was then estimated
comparing pooled counts of risk alleles with counts of alleles of
23 repeats or fewer. Where a cell contained zero observations, a
continuity correction of 0.5 was applied. The sample size was
considered adequate to measure the effect size since each indi-
vidual study in the meta-analysis measured the effect, and the
addition of further samples would increase power further. We
assumed that all studies were estimating the same common effect
and estimates varied only because of chance differences in sam-
pling patients. To assess our assumption, heterogeneity between
studies was estimated using the I2 statistic (% of variability due to
between-study heterogeneity) and Cochrane’s Q-test of heteroge-
neity. I2 > 50% or p < 0.05 for the Q-test were taken as indicative of
signiﬁcant heterogeneity. We used a ﬁxed effects model following
the assumption that all studies had a common genetic effect and
that speciﬁc ﬁndings of each study were due to random sampling.
However, to control for any possible difference across studies, the
ﬁxed effect model RR estimates at each threshold were compared
with RR estimates assessed using a random effects model. A
sensitivity analysis, leaving out one study at a time, was performed
to test the robustness of the meta-analysis and assess the inﬂuence
of individual studies on the overall result for each allele. Possible
sources of heterogeneity across studies were explored using
subgroup analysis using source of the control group (population
based vs. nonpopulation based) and geographic location (China,
Europe, Turkey, USA) as covariates. Meta-regression was used to
further investigate differences between population-based and
nonpopulation-based subgroups. Funnel plots were generated for
each intermediate repeat allele to analyze the intervention effect
from individual studies against study size. A resulting p < 0.05 was
considered as indicative of the presence of small-study effects.
Correlation between age at onset and the CAG trinucleotide repeat
 B            A
Fig. 1. Distribution of ATXN2 alleles with trinucleotide repeat size 24 or more in the (A) British and (B) Dutch datasets. (A) The British dataset included 1474 ALS individuals and
574 controls. There were 2867 alleles of size 23 or less in cases and 1105 in controls. (B) The Dutch dataset included 1328 ALS individuals and 691 controls. There were 2596 alleles of
size 23 or less in cases and 1344 in controls.
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length of risk alleles was tested in the new British and Dutch ALS
cases, and in published data sets for which age at onset data were
available. Two-tailed Fisher exact tests were used to test for dif-
ferences in demographic and clinical characteristics of patients by
ATXN2 repeat size. ANOVA was used to compare ages at onset for
different repeat sizes, as well as by using SNPs rs695871 and
rs695872, previously shown to associate with age of onset. Kaplan-
Meier survival analysis and a log-rank test were used to compare
survival time between groups. We compared the ﬁt of an expo-
nential model with the ﬁt of a linear model using Akaike infor-
mation criteria and Bayesian information criteria. Comparison of
model values for either measure can be used to assess ﬁt provided
the values differ by more than 10. The model with the larger value
has less support (Burnham and Anderson, 2002; Raftery, 1995).
Meta-analyses were performed using STATA version 12.0 (Stata
Corp, College Station, TX, USA). Chi-square tests, ANOVA, and
Kaplan-Meier survival analysis were performed using SPSS statis-
tical package version 22 (IBM, Chicago, IL, USA). R language (http://
www.R-project.org) was used to test the hypothesis that the rela-
tionship between ATXN2 CAG repeat length and ALS risk ﬁtted an
exponential model.
3. Results
ATXN2 trinucleotide CAG repeats were analyzed in 1474 ALS
cases and 567 neurologically normal controls from the UK and in
1328 ALS cases and 691 neurologically normal controls from
the Netherlands. The distribution of allele frequencies is shown
in Fig. 1.
All cases were tested for the copresence of ATXN2 intermediate
expansions and C9orf72 expansion. Six patients (2 UK, 4 Dutch) had
intermediate ATXN2 expansion and pathological expansion of
C9orf72. Exclusion of these patients from analyses did not change
the overall ﬁndings.
Based on literature searches (Fig. 2), we identiﬁed all known
studies examining ATXN2 repeat expansion in ALS, contacting
authors for raw data where necessary, and including studies for
analysis based on strict criteria (Supplementary Table 1). Studies
passing inclusion criteria (Conforti et al., 2012; Corrado et al., 2011;
Daoud et al., 2011; Elden et al., 2010; Gellera et al., 2012; Gispert
et al., 2012; Lahut et al., 2012; Lattante et al., 2014; Lee et al.,
2011; Liu et al., 2013; Lu et al., 2015; Ross et al., 2011; Soong
et al., 2014; Sorarù et al., 2011; Van Damme et al., 2011; Van
Langenhove et al., 2012) and the 2 novel datasets were used. One
Chinese dataset (Chen et al., 2011) was excluded because the
authors were unable to provide information on the control group.
We excluded studies that might show bias according to the
Newcastle-Ottawa Scale criteria (Supplementary Table 2), leaving a
total of 15 studies for meta-analysis, comprising 10,888 cases and
15,463 controls (Supplementary Fig. 1). The allele counts of pooled
alleles <24 repeats and of each allele with 24 trinucleotide repeats
or greater are reported in Supplementary Table 3. No evidence of
small-study effect was found in any of the primary analysis studies
(data not shown), although we acknowledge that the Funnel plots
are not independent of each other.
We ﬁrst established the deﬁnitive size range ascribing risk for
ALS, investigating each allele from 24 repeats to 34 repeats by
using a ﬁxed effects approach (Supplementary Table 4). The
exclusion of the study published by Liu et al. (2013) from analysis
of the RR conferred by the 30 repeat allele lowered the initial
signiﬁcant heterogeneity (I2¼ 48.8%, heterogeneity p¼ 0.02) to an
overall I2 value of 0% (heterogeneity p¼ 0.51) but did not inﬂuence
the overall RR estimate. No study exclusion could explain the
signiﬁcant heterogeneity present in the analysis of the 24 repeat
allele. No other studies had any effect on heterogeneity or
RR estimates, including 2 studies that used young controls below
the age of risk (Corrado et al., 2011; Elden et al., 2010), and there
was no effect of ancestral background of the population studied.
249 Records identified through 
PubMed database searching
between August 1, 2010 and 
November 30, 2014. 
Search words: ALS,   
amyotrophic lateral sclerosis, 
SCA2, ATXN2, Ataxin 2, CAG 
repeats, intermediate  
expansion.
63 Records retained and reviewed 
by title screening
186 Records excluded because 
duplicates
21 Full-text articles assessed for    
eligibility
21 Articles excluded: 
3 Meta-analysis 
5 Case series  
7 Editorial or Review
5 Mechanism studies
1 Screening study
7 Studies included in qualitative 
synthesis
16 Studies included in qualitative   
synthesis.
14 Article excluded:
10 Case-control studies with    
insufficient  
published information
3 Studies used published data 
1 Case-control study included 
only cases with C9ORF72 
expansions  
9 Articles included after First 
and Senior author provided 
missing Information
18 Studies included in qualitative  
synthesis.
2 Non-published case-control 
datasets with complete  
information included in the 
meta-analysis
42 Records reviewed by abstract 
screening
21 Records excluded because 
not relevant
15 Studies were included in 
quantitative synthesis. 
(Meta-analysis)
3 Published case-control 
datasets excluded according to 
NOS criteria.
Fig. 2. Flow chart of study selection according to the PRISMA protocol. Thirteen pre-
viously published studies were selected for analysis, 7 from Europe (Conforti et al.,
2012; Corrado et al., 2011; Daoud et al., 2011; Gispert et al., 2012; Lattante et al.,
2014; Van Damme et al., 2011; Van Langenhove et al., 2012), 3 studies of Han Chi-
nese (2 from China [Liu et al., 2013; Lu et al., 2015] and 1 from Taiwan [Soong et al.,
2014]), 1 from Turkey (Lahut et al., 2012), and 2 studies from the USA (Elden et al.,
2010; Ross et al., 2011).
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Using a random effects model did not change the ﬁndings
(Supplementary Table 5).
We found that alleles with 29e33 repeats were associated with
ALS (Fig. 3). A meta-analysis of the pooled counts of the risk alleles
showed a RR of ALS of 3.06, 95% CI, 2.37e3.94, p¼ 6 1018 (Fig. 4).
We performed a sensitivity analysis, reintroducing the 3 studies
excluded for risk of bias, which did not affect the results (data not
shown).
Investigating the effect size of each allele, we found that the
risk increased exponentially with length for alleles of 29e32
repeats (R2 ¼ 0.91 [95% CI 0.82, 0.99], p ¼ 0.0002; Fig. 5), only
dropping off at the boundary for risk of spinocerebellar ataxia type
2, at 33 repeats. This is surprising and has not been reported for
any trinucleotide repeat disease. The goodness-of-ﬁt of the
exponential model was compared with the ﬁt of a linear model.
The exponential model gave a better ﬁt based on Akaike infor-
mation criteria and Bayesian information criteria criteria
(Supplementary Table 6).
Next, we tested the relationship between repeat length and
age of ALS onset in the 4 different populations for which data
were available. In keeping with previous ﬁndings, and in contrast
to trinucleotide repeat diseases, we found no evidence for such a
relationship (UK [n ¼ 17] age at onset-repeat length regression,
p ¼ 0.90; the Netherlands [n ¼ 37] age at onset-repeat length
regression, p ¼ 0.08; Belgium [Van Damme et al., 2011; n ¼ 25]
age at onset-repeat length regression, p ¼ 0.83; France [Lattante
et al., 2014; n ¼ 33] age at onset-repeat length regression, p ¼
0.49; Flanders-Belgian [Van Langenhove et al., 2012; n ¼ 4] age at
onset-repeat length regression, p ¼ 0.60; overall age at onset-
repeat length regression, p ¼ 0.14). Nor were there any associa-
tions when SNPs rs695871 and rs695872, previously shown to
associate with the age of onset, were tested.
We also assessed differences in demographic and clinical char-
acteristics between patients with CAG repeats <29 and patients
with CAG repeats 29 in both British and Dutch cohorts. No sig-
niﬁcant difference was found in gender, age at onset, or site of
onset (Supplementary Table 7). No signiﬁcant difference in survival
was detected by Kaplan-Meier analysis in either the British
(p-value ¼ 0.87) or Dutch (p-value ¼ 0.31) cohorts.
4. Discussion
We have found the risk range for ATXN2 trinucleotide repeat
alleles in ALS is 29e33. An unexpected and important ﬁnding is
that the risk of ALS increases exponentially with allele repeat size
until the border with spinocerebellar ataxia risk, even though the
age of onset does not change. This may appear surprising but is
entirely consistent with current hypotheses of ALS causation, in
which the odds ratio conferred by genetic variants and age of
onset of ﬁrst symptoms are not correlated, even within the
same family (e.g., TARDBP, FUS; Abel et al., 2012; Al-Chalabi and
Hardiman, 2013; van Rheenen et al., 2016). Our conﬁdence in the
ﬁnding of an exponential increase in risk is high because this is the
largest study of ATXN2 alleles and ALS, our ﬁndings overall are
consistent with previous studies, and 4 different European pop-
ulations gave identical results for the relationship of age of onset
with trinucleotide allele repeat size. Furthermore, an exponential
ﬁt is strongly supported statistically over a linear change in risk.
The fact the risk drops off at 33 repeats can be interpreted as a
dilution in the case ascertainment, since a large proportion of
people with 33 repeats would develop spinocerebellar ataxia
(Fernandez et al., 2000) rather than ALS, but we have ascertained
on disease state rather than repeat size. To ascertain repeat size,
we used a method previously reported to include unrelated PCR
products in the critical range of the gel (Pulst et al., 1996). To
overcome this limitation, we genotyped all samples twice.
The trinucleotide repeat size range we found associated with
risk of ALS overlappedwith but was larger than previously reported
ranges, (probably because the increased sample size improved our
statistical power), and has implications for genetic counseling of
individuals carrying intermediate size repeats. Two published
meta-analyses, one of 12 and another of 13 studies, reported sig-
niﬁcant association with ALS for pooled analyses of ATXN2 alleles
greater than 30 trinucleotide repeats, a ﬁnding that remained sig-
niﬁcant when restricted to alleles sized between 30 and 33 repeats
(Lafﬁta-Mesa et al., 2012; Wang et al., 2014). Another meta-analysis
of 9 studies found that individual ATXN2 allele frequencies of 31, 32,
and 33 repeats were signiﬁcantly higher in ALS cases than in con-
trols (Neuenschwander et al., 2014).
Overall  (I-squared = 48.8%, p = 0.021)
Dataset-NL
Conforti et al. 2012
Corrado et al. 2011
Elden et al. 2010
Soong et al. 2014
Liu et al. 2013
Lahut et al. 2012
Lu et al. 2014
Van Langenhove et al. 2012
Gispert et al. 2012
Ross et al. 2011
Dataset-UK
Daoud et al. 2011
Lattante et al. 2014
Van Damme et al. 2011
2.02 (1.30, 3.15)
1.04 (0.19, 5.65)
4.33 (0.52, 35.87)
0.57 (0.02, 13.91)
9.78 (0.53, 181.57)
1.28 (0.05, 31.32)
0.20 (0.05, 0.79)
(Excluded)
4.62 (0.42, 50.85)
23.27 (2.12, 255.00)
7.31 (0.76, 70.24)
9.30 (2.33, 37.15)
2.31 (0.28, 19.16)
2.57 (0.27, 24.70)
4.78 (0.60, 38.20)
1.35 (0.36, 5.02)
100.00
10.45
4.61
4.40
1.90
2.46
37.56
0.00
2.40
0.63
2.31
3.08
5.73
4.27
4.96
15.25
1.00392 255
Relative Risk                 Weight          
(95% CI)                        % 
Overall  (I-squared = 0.0%, p = 0.610)
Corrado et al. 2011
Lattante et al. 2014
Van Damme et al. 2011
Elden et al. 2010
Lu et al. 2014
Gispert et al. 2012
Soong et al. 2014
Van Langenhove et al. 2012
Dataset-UK
Lahut et al. 2012
Dataset-NL
Liu et al. 2013
Daoud et al. 2011
Conforti et al. 2012
Ross et al. 2011
1.68 (1.11, 2.54)
0.34 (0.04, 2.92)
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Fig. 3. Forest plots of individual alleles between 29 and 33 repeats. Primary analysis of the relative risk of ALS was conducted using low risk-bias case-control studies. UK ¼ new UK
data, NL ¼ new Dutch data. Relative risk (RR) was estimated using a ﬁxed effects approach and by comparing individual counts of ATXN2 alleles with the pooled count of alleles with
23 repeats as baseline. (A) ATXN2 allele of 29 repeats, RR ¼ 1.68 (1.11, 2.54). No heterogeneity was observed (p-value of heterogeneity >0.05). (B) ATXN2 allele of 30 repeats, RR ¼
2.02 (1.30, 3.15). One of 15 studies was excluded for absence of carriers of allele 30, both in cases and controls. Signiﬁcant heterogeneity was observed (p-value of heterogeneity
<0.05). (C) ATXN2 allele of 31 repeats, RR ¼ 2.96 (1.73, 5.05). One of 15 studies was excluded for absence of carriers of allele 31, both in cases and controls. No heterogeneity was
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It has been suggested that shorter intermediate repeats may be
protective for ALS (Neuenschwander et al., 2014). Our data are
consistent with this possibility, and indeed for alleles of 27 repeats,
show a signiﬁcant protective effect (Fig. 5, Supplementary Table 4).
Previous studies of the ATXN2 repeat length in ALS have not shown
a relationship with age of onset (Lafﬁta-Mesa et al., 2012;
Neuenschwander et al., 2014; Wang et al., 2014). In this study,
5 populations comprising 5703 cases of the 10,888 individuals
studied had age of onset data available. Despite this limitation in
numbers, there is unlikely to be a major effect of allele size on the
age of onset for ALS. A recent study reported a modiﬁer effect of
ATXN2 intermediate length repeats on ALS survival for those with
31 or more repeats (Chiò et al., 2015). We did not replicate this
ﬁnding.
The mechanism by which expanded trinucleotide repeats cause
disease does not appear to be the same for all such diseases, even
though all trinucleotide repeat expansions result in neurological
dysfunction. In some cases, there is a loss of function, for example
through hypermethylation (Jin and Warren, 2000), whereas in
others, there is a toxic gain of function, for example through
aggregation following protein misfolding (Kayatekin et al., 2014).
For toxic products of affected genes, larger expansions are likely to
result in increased toxicity, and since the products are present from
birth, an earlier age of onset or more severe phenotype is the likely
outcome of larger repeat sizes. Here, we can add a third outcome of
larger repeats: that the risk of disease increases. This can be
explained within the recently proposed multistep model of ALS if
the toxic effect of intermediate expansions is one of the steps
required for ALS to develop, and the toxic effect shows a correlation
with repeat size (Al-Chalabi et al., 2014). It also allows for the
possibility of oligogenic inheritance, where multiple genetic risk
factors act in concert to cause ALS. The mechanism by which this
might happen without a concomitant reduction in age of onset
remains to be determined. A possible explanation lies in the exis-
tence of CAA interruptions to the CAG trinucleotide repeat
sequence. Aweakness of this study is that such interruptions would
not be detectable using our assay but would merely appear as
additional CAG repeats. Up to 3 such interruptions have been
observed in the ATXN2 trinucleotide repeat by direct sequencing
but become less likely as the length of the repeat increases. When
CAA interruptions occur in repeats of size 33e40, the phenotype is
usually of a dopa-responsive Parkinsonism (Kim et al., 2007). One
mechanism for risk associated with CAG repeats is through RNA
toxicity, and CAA interruptions speciﬁcally alter RNA secondary
structure. The formation of a stable RNA hairpin structure could be
associated with the position and number of CAA triplets along
the CAG expansion leading to an RNA toxic gain of function
(Yu et al., 2011). Thus the interruptions can modify phenotype, and
E
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Fig. 4. Forest plot of the relative risk of ALS for ATXN2 alleles with 29e33 trinucleotide repeats. UK ¼ new UK data, NL ¼ new Dutch data. Fifteen studies at low risk of bias were
included. Fixed effects methods were used to estimate the relative risk. No heterogeneity was observed (p-value of heterogeneity >0.05). Abbreviation: ALS, amyotrophic lateral
sclerosis.
Fig. 5. Plot of the relative risk for each ATXN2 allele (25e32 repeats). The distribution of the relative risk estimates of alleles of between 25 and 32 CAG trinucleotide repeats
obtained from the 15 low bias studies ﬁtted an exponential curve well, showing an exponential growth in relative risk, surpassing the threshold for signiﬁcant association for alleles
of size 29e32 (R2 ¼ 0.91 [95% CI 0.82, 0.99], p ¼ 0.0002). The relative risk estimate of the 24 repeat allele was excluded because of a large unidentiﬁed heterogeneity across studies.
Including this allele, however, did not signiﬁcantly change the curve ﬁt. Black bars indicate the 95% CI of the relative risk estimates. The red line indicates no effect. Abbreviation:
CI, conﬁdence interval.
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an interaction between repeat length and CAA interruption could
underlie ALS risk and the lack of effect on the age of onset.
Furthermore, although both Dutch and UK cohorts had individuals
with more than 33 repeats, they did not have spinocerebellar
ataxia, a ﬁnding which might be related to CAA interruptions.
5. Conclusion
Our study increases the breadth of known effects of trinucleo-
tide repeat expansion size, adding disease risk to the existing cor-
relations with age of onset and disease severity. Thus, the main
ﬁnding presented here is that trinucleotide repeat expansion in the
ATXN2 gene in the size range exclusively for ALS risk represents an
exponentially increasing risk for each additional repeat.
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